Bertocci, M A
Bebko, G
Versace, A
Fournier, J C
Iyengar, S
Olino, T
Bonar, L
Almeida, J R C
Perlman, S B
Schirda, C
Travis, M J
Gill, M K
Diwadkar, V A
Forbes, E E
Sunshine, J L
Holland, S K
Kowatch, R A
Birmaher, B
Axelson, D
Horwitz, S M
Frazier, T W
Arnold, L E
Fristad, M A
Youngstrom, E A
Findling, R L
Phillips, M L
Article History
Received: 30 July 2015
Revised: 9 October 2015
Accepted: 2 December 2015
First Online: 23 February 2016
Competing interests
: Bertocci, Bebko, Olino, Fournier, Iyengar, Horwitz, Axelson, Holland, Schirda, Versace, Almeida, Perlman, Diwadkar, Travis, Bonar, Gill and Forbes have no financial interests or potential conflict of interest. Dr Findling receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Alcobra, American Academy of Child & Adolescent Psychiatry, American Physician Institute, American Psychiatric Press, AstraZeneca, Bracket, Bristol-Myers Squibb, CogCubed, Cognition Group, Coronado Biosciences, Dana Foundation, Elsevier, Forest, GlaxoSmithKline, Guilford Press, Johns Hopkins University Press, Johnson and Johnson, Jubilant Clinsys, KemPharm, Lilly, Lundbeck, Merck, NIH, Neurim, Novartis, Noven, Otsuka, Oxford University Press, Pfizer, Physicians Postgraduate Press, Purdue, Rhodes Pharmaceuticals, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Transcept Pharmaceuticals, Tris, Validus, and WebMD. Dr Frazier has received federal funding or research support from, acted as a consultant to, received travel support from and/or received a speaker’s honorarium from the Cole family research fund, the Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, National Institutes of Health and the Brain and Behavior Research Foundation. Dr Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Arbor, Gowlings, Ironshore, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, Tris Pharma, and Waypoint and received travel support from Noven. Dr Youngstrom has consulted with Pearson, Lundbeck and Otsuka about assessment, as well as having grant support from the NIH. Dr Fristad receives royalties from Guilford Press, APPI, CFPSI and is a consultant to Physicians Postgraduate Press and Western Psychological Services. Dr Birmaher receives royalties from for publications from Random House (New hope for children and teens with bipolar disorder) and Lippincott Williams & Wilkins (Treating Child and Adolescent Depression). He is employed by the University of Pittsburgh and the University of Pittsburgh Medical Center and receives research funding from NIMH. Dr Kowatch is a consultant for Forest Pharmaceutical and the REACH Foundation. He is employed by the Ohio State Wexner Medical Center. Dr Sunshine receives research support from Siemens Healthcare, Dr Phillips is a consultant for Roche.